Cassava Sciences Inc (SAVA)
28.48
-3.38
(-10.62%)
USD |
NASDAQ |
Sep 27, 16:00
28.47
-0.02
(-0.05%)
After-Hours: 20:00
Cassava Sciences SG&A Expense (Annual): 16.53M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.53M |
| December 31, 2022 | 11.99M |
| December 31, 2021 | 8.055M |
| December 31, 2020 | 3.739M |
| December 31, 2019 | 3.391M |
| December 31, 2018 | 3.693M |
| December 31, 2017 | 4.334M |
| December 31, 2016 | 5.781M |
| December 31, 2015 | 5.102M |
| December 31, 2014 | 5.127M |
| December 31, 2013 | 4.837M |
| December 31, 2012 | 7.182M |
| December 31, 2011 | 6.698M |
| Date | Value |
|---|---|
| December 31, 2010 | 14.77M |
| December 31, 2009 | 6.258M |
| December 31, 2008 | 9.196M |
| December 31, 2007 | 8.085M |
| December 31, 2006 | 7.668M |
| December 31, 2005 | 4.859M |
| December 31, 2004 | 3.868M |
| December 31, 2003 | 3.338M |
| December 31, 2002 | 5.523M |
| December 31, 2001 | 5.647M |
| December 31, 2000 | 7.709M |
| December 31, 1999 | 2.567M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
3.391M
Minimum
2019
16.53M
Maximum
2023
8.741M
Average
8.055M
Median
2021
SG&A Expense (Annual) Benchmarks
| Bristol-Myers Squibb Co | 7.772B |
| Eli Lilly and Co | 6.941B |
| Seelos Therapeutics Inc | 12.58M |
| Moderna Inc | 1.549B |
| Biomarin Pharmaceutical Inc | 937.30M |